Anidulafungin

06/01/2021 - "Approximately 7 out of 10 (72%) patients were cured or no longer had signs of Candida infection at the end of IV anidulafungin treatment. "
08/01/2009 - "Our data suggest that the efficacy of anidulafungin in the treatment of candidiasis might stem from both direct fungicidal activity and indirect PAFEs that lessen the ability of Candida cells to establish invasive disease and to persist within infected hosts."
01/01/2017 - "Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis."
10/01/2019 - "Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies."
01/01/2017 - "In a mouse model of disseminated candidiasis, the test compounds displayed clear dose responses and were generally associated with lower fungal burdens than that of anidulafungin. "

06/01/2013 - "We investigated the pathogenic role of biofilm and the therapeutic efficacy of anidulafungin in experimental infections of the wax moth Galleria mellonella by Candida albicans clinical strains. "
02/01/2012 - "In conclusion, anidulafungin distributes to bone, brain, and heart tissues of neonatal rats; such results are supportive of further investigation of efficacy against infections involving bone, brain, and heart tissues. "
03/01/2011 - "In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus."
11/23/2021 - "nivariensis infections while anidulafungin was during C. "
09/01/2019 - "To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the peritoneal cavity. "

06/01/2004 - "The clearance of anidulafungin was influenced by weight and gender, and subjects in the invasive candidiasis study had a typical clearance that was approximately 30% higher than subjects from other studies. "
01/01/2017 - "These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive candidiasis in a broad patient population."
01/01/2019 - "A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age."
01/01/2017 - "Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials."
01/01/2003 - "In January 2003, Versicor announced that positive results from a phase II trial for anidulafungin IV treatment involving 120 patients in the US with invasive candidiasis/candidaemia, have led to another double-blind, randomised phase III trial being conducted in the US, Canada and Europe for this indication. "

12/01/2010 - "Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."
11/01/2005 - "In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. "
05/15/2013 - "Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different. "
02/01/2022 - "Larger studies are needed to confirm whether standard doses of anidulafungin are sufficient for candidemia in obese patients."
05/15/2013 - "An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. "

01/01/2007 - "After promising results from animal models, the role of anidulafungin in the treatment of invasive aspergillosis and other filamentous fungi is yet to be cleared. "
01/01/2013 - "Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis."
09/01/2004 - "Although the activity of anidulafungin in animal models of pulmonary or disseminated aspergillosis shows increased survival and improvement in the pulmonary infarct score, the effect on residual fungal burden and Aspergillus antigenemia determination does not indicate in vivo fungicidal activity. "
02/01/2008 - "On the other hand, there is insufficient evidence as of yet to support first-line use of anidulafungin in patients with neutropenia or aspergillosis."
04/01/1998 - "Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis."